Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry-s Success

Research Driven Investing Provides Stocks Research on ImmunoGen and Omeros

Continue Reading

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Research Driven Investing Provides Stocks Research on Athersys and Rexahn Pharmaceuticals

Continue Reading

FDA Approved a Total of 39 New Drugs in 2012 — Fifteen Year High

Research Driven Investing Provides Stocks Research on AEterna Zentaris and Oncolytics Biotech

Continue Reading

Nevada Casinos Revenues Total $10.86 Billion in 2012 — Third Consecutive Annual Increase

RDInvesting Provides Stock Research on Caesars Entertainment and MGM Resorts International

Continue Reading

Biotechnology Industry Soars in 2012 as FDA Drug Approvals at a 15-Year High

Research Driven Investing Provides Stocks Research on Alnylam and Arena

Continue Reading

Las Vegas Sands and Wynn Resorts Rise as Gambling Revenues in Nevada Surge 10 Percent in December

RDInvesting Provides Stock Research on Las Vegas Sands and Wynn Resorts

Continue Reading

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Research Driven Investing Provides Stocks Research on Optimer Pharmaceuticals and Santarus

Continue Reading

Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry-s Success

Research Driven Investing Provides Stocks Research on Amicus Therapeutics and Novavax

Continue Reading

Total Health Care Spending Projected Grow 70% by 2021

Research Driven Investing Provides Stocks Research on Mylan and Teva Pharmaceutical

Continue Reading

Centers for Medicare and Medicaid Services Projects Health Care Spending to Grow From $2.8 Trillion to $4.8 Trillion by 2021

Research Driven Investing Provides Stocks Research on CIGNA and Express Scripts

Continue Reading